Director Share Purchase

Arix Bioscience PLC (ARIX) Director Share Purchase 21-Dec-2020 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience plc Director Share Purchase LONDON, 21 December 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Naseem Amin, Executive Chairman, purchased 183,000 ordinary shares ("Ordinary Shares") in the Company on 18 December 2020 at a price of 206p per share, via a corporate entity in which he has a majority beneficial interest. The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the transaction in number of Ordinary Shares.  PDMR DEALING NOTIFICATION Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Naseem Amin 2 Reason for the notification a) Position / status Executive Chairman b) Initial notification / Amendment Initial Notification 3 Details of issuer a) Name Arix Bioscience plc b) LEI 213800OVT3AHQCXNIX43 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary Shares of Arix Bioscience plc Identification code GB00BD045071 b) Nature of the transaction Purchase of Ordinary Shares by Davum Capital Limited, a corporate entity in which Naseem Amin has a majority beneficial interest c) Price(s) and volume(s) Price(s) Volume(s) 206.00p 183,000 d) Aggregated information Aggregated price Aggregated volume N/A (single transaction) N/A (single transaction) e) Date of the transaction 18 December 2020 f) Place of the transaction London Stock Exchange (XLON) For further information: Robert Lyne Chief Operating Officer and General Counsel [phone]  - Ends -

ISIN:	GB00BD045071
Category Code:	DSH
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
Sequence No.:	90018
EQS News ID:	1156507

End of Announcement	EQS News Service